News

April 2, 2008 - Cyprotex introduces new product line Cloe® Select

Cyprotex introduces new product line Cloe® Select - a portfolio of bespoke ADME and PK services.

Today, (2nd April 2008), Cyprotex announces that it is introducing a new product line, Cloe® Select. Cloe® Select is a portfolio of bespoke studies which can be customised to individual customer requirements. It complements the current range of Cloe® Screen assays to provide ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic solutions from early discovery through to later stage development projects. As with Cloe® Screen, Cloe® Select meets the criteria set by the regulatory guidelines to provide constant confidence in the quality of the data.

The drug discovery and development process represents a number of pre-clinical phases which cover hit to lead, lead optimization and candidate selection. Cyprotex can now offer a fully integrated solution in the area of ADME and pharmacokinetics throughout this entire process. We have gained extensive knowledge in our field over the past 9 years, which is attributed to investing in high caliber committed scientists and by working with a large and diverse customer base.

Mr Robert Atwater, Cyprotex's Chief Executive Officer, comments on the launch of this new product line. "Many of our customers rely on us for their ADME projects right from early screening projects through to IND submission. Building these relationships and ensuring that we can offer a flexible and broad range of screening options has been critical in the success of our business."

Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. Our unique Cloe® Screen technology which couples robust protocols with state-of-the-art automation enables Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround. Introducing Cloe® Select ensures that Cyprotex can extend their offering to later stage more in-depth studies which require a more flexible approach. Cyprotex also has extensive expertise in physiologically based pharmacokinetic (PB-PK) modelling and quantitative structure activity relationship (QSAR) modelling techniques under its Cloe® Predict service. In combination, Cloe® Screen, Cloe® Select and Cloe® Predict offer an integrated solution for both experimental screening and prediction, fulfilling the needs of our broad and varied customer base.

For further information:
Cyprotex PLC
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100
h.gill@cyprotex.com
www.cyprotex.com